Clinical, Trichoscopic, and Folliscopic Identification of the Impact of Metabolic Syndrome on the Response to Intradermal Dutasteride 0.02% Injection in Patients with Female Pattern Hair Loss: A Prospective Cohort Study

    Nayera H. Moftah, Rana Mubarak, Rania Abdelghani
    Image of study
    TLDR Metabolic syndrome reduces effectiveness of hair loss treatment.
    A prospective cohort study investigated the impact of metabolic syndrome (MetS) on the response to intradermal dutasteride 0.02% injection in female pattern hair loss (FPHL) patients. The study involved 51 women, with 26 having MetS and 25 without. The study found that MetS can decrease the effectiveness of intradermal dutasteride 0.02% injection for FPHL, resulting in a lower percentage of terminal hair and a higher percentage of vellus hair. However, further research is needed to confirm these findings. Trichoscopy and folliscopy were used to evaluate treatment response. The study also found that the duration of FPHL was significantly related to changes in hair thickness after treatment in patients with MetS.
    View this study on tandfonline.com →

    Cited in this study

    37 / NoResults

    Related

    9 / NoResults